IVA

MKT CAP:$267M

Inventiva S.A.

Market Cap

$267M

Healthcare·Biotechnology·🇫🇷 France·NASDAQ

Healthcare·Biotechnology·🇫🇷·NASDAQ

Stock Price

$5.21+$0.45 (+9.45%)

Apr 23, 2026

Company Details

Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH), mucopolysaccharidoses (MPS), and other diseases. Its lead pro...

CEO

Pierre Broqua

IPO Date

Jul 10, 2020

Website

www.inventivapharma.com

Key Metrics TTM

Revenue

$16M

-65.1% YoY

Net Income

-$628M

EPS (Diluted)

-$6.36

Free Cash Flow

-$228M

Revenue / Share

$0.02

Gross Margin

79.8%

Operating Margin

-1661.2%

Net Margin

-3976.8%

FCF Margin

-1441.5%

P/S

16.9x

P/E

—

Earnings Reports

FY 2025

Apr 8, 2026

$5M-53.2%EPS -$2.13

Q4 2025

Apr 8, 2026

-$173.0K-102.3%EPS -$0.33

Q2 2025

Jun 29, 2025

$5M+62.9%EPS -$1.89

FY 2024

Apr 15, 2025

$11M-47.4%EPS -$4.14

Q4 2024

Apr 15, 2025

$8M-60.9%EPS -$3.04

Revenue & Profitability

Quarter	Revenue	Gross Profit	Operating Income
Q2 18	$5M	$4M	-$19M
Q4 18	$4M	$3M	-$20M
Q2 19	$4M	$4M	-$24M
Q4 19	$7M	$6M	-$14M
Q2 20	$86.5K	$86.5K	-$10M
Q4 20	$246.7K	-$319.2K	-$18M
Q2 21	$76.0K	$76.0K	-$16M
Q4 21	$5M	$4M	-$36M
Q2 22	$78.3K	-$530.8K	-$43M
Q4 22	$18M	$17M	-$28M
Q2 23	$8M	$7M	-$64M
Q4 23	$19M	$19M	-$56M
Q2 24	$3M	$3M	-$61M
Q4 24	$8M	$8M	-$53M
Q2 25	$5M	$3M	-$66M
Q4 25	-$173.0K	-$1M	-$82M

Valuation

Quarter	P/S	P/E
Q2 18	16.4x	—
Q4 18	20.5x	—
Q2 19	22.8x	—
Q4 19	21.5x	—
Q2 20	28.5x	—
Q4 20	44.1x	—
Q2 21	64.4x	—
Q4 21	108.4x	—
Q2 22	52.1x	—
Q4 22	9.5x	—
Q2 23	6.3x	—
Q4 23	4.9x	—
Q2 24	3.1x	—
Q4 24	3.1x	—
Q2 25	4.7x	—
Q4 25	31.4x	—

Operating Cash Flow

Quarter	Operating CF	Free CF
Q2 18	-$18M	-$18M
Q4 18	-$22M	-$22M
Q2 19	-$22M	-$22M
Q4 19	-$11M	-$11M
Q2 20	-$4M	-$4M
Q4 20	-$27M	-$28M
Q2 21	-$14M	-$14M
Q4 21	-$33M	-$33M
Q2 22	-$31M	-$31M
Q4 22	-$22M	-$22M
Q2 23	-$53M	-$53M
Q4 23	-$43M	-$43M
Q2 24	-$57M	-$57M
Q4 24	-$44M	-$44M
Q2 25	-$63M	-$63M
Q4 25	-$63M	-$64M

Capital Expenditures

Quarter	CapEx
Q2 18	$309.8K
Q4 18	$208.1K
Q2 19	$170.7K
Q4 19	$11.7K
Q2 20	$0
Q4 20	$341.4K
Q2 21	$136.8K
Q4 21	$439.6K
Q2 22	$346.1K
Q4 22	$309.8K
Q2 23	$268.9K
Q4 23	$362.4K
Q2 24	$298.1K
Q4 24	$91.2K
Q2 25	$66.6K
Q4 25	$224.7K

CapEx

OpEx vs Revenue Growth (YoY)

Quarter	Revenue Growth	OpEx Growth
Q2 18	-38.3%	+51.5%
Q4 18	-57.6%	+48.7%
Q2 19	-32.7%	+45.8%
Q4 19	+20.4%	+3.4%
Q2 20	-98.2%	-55.8%
Q4 20	-93.5%	-20.6%
Q2 21	-98.2%	-43.2%
Q4 21	-28.4%	+101.2%
Q2 22	-9.5%	+309.5%
Q4 22	+7209.0%	+145.1%
Q2 23	+10087.7%	+348.9%
Q4 23	+307.9%	+84.9%
Q2 24	+3980.6%	+50.3%
Q4 24	-58.1%	+32.6%
Q2 25	-32.7%	-0.6%
Q4 25	-100.9%	+8.7%

Stock-Based Compensation

Quarter	SBC ($)	% of Revenue
Q2 18	$588.1K	12.1%
Q4 18	$385.8K	10.2%
Q2 19	$840.6K	20.4%
Q4 19	$804.4K	12.1%
Q2 20	$646.6K	747.3%
Q4 20	$450.1K	182.5%
Q2 21	$728.4K	958.5%
Q4 21	$2M	36.2%
Q2 22	$2M	2452.2%
Q4 22	$672.3K	3.7%
Q2 23	$2M	30.9%
Q4 23	$2M	11.6%
Q2 24	$0	0.0%
Q4 24	$4M	55.4%
Q2 25	$0	0.0%
Q4 25	$0	—

OpEx Breakdown

Quarter	R&D	G&A	S&M	SG&A
Q2 18	$19M	$4M	$125.1K	—
Q4 18	$19M	$3M	$134.5K	—
Q2 19	$23M	$3M	$166.0K	—
Q4 19	$16M	$3M	$123.9K	—
Q2 20	$8M	$2M	$4.7K	—
Q4 20	$13M	$5M	$523.8K	—
Q2 21	$14M	$4M	$80.7K	—
Q4 21	$34M	$6M	$123.9K	—
Q2 22	$34M	$7M	$315.7K	—
Q4 22	$36M	$7M	$3M	—
Q2 23	$63M	$7M	$812.6K	—
Q4 23	$65M	$8M	$1M	—
Q2 24	$55M	$8M	$687.5K	—
Q4 24	$52M	$9M	$2M	—
Q2 25	$51M	—	—	$19M
Q4 25	$50M	—	—	$42M

War Chest

Quarter	Cash	Short-term Investments	Total
Q2 18	$89M	$0	$89M
Q4 18	$66M	$0	$66M
Q2 19	$43M	$0	$43M
Q4 19	$42M	$0	$42M
Q2 20	$61M	$0	$61M
Q4 20	$124M	$0	$124M
Q2 21	$109M	$0	$109M
Q4 21	$101M	$0	$101M
Q2 22	$89M	$13M	$102M
Q4 22	$101M	$1M	$103M
Q2 23	$37M	$58.5K	$37M
Q4 23	$31M	$81.8K	$32M
Q2 24	$12M	$0	$12M
Q4 24	$113M	$0	$113M
Q2 25	$143M	$0	$143M
Q4 25	$116M	$0	$116M

Shares Outstanding

Quarter	Shares (Diluted)	QoQ Change	YoY Change
Q2 18	19M	+15.1%	+88.0%
Q4 18	22M	+17.8%	+121.6%
Q2 19	22M	-0.3%	+51.3%
Q4 19	27M	+20.8%	+63.4%
Q2 20	31M	+15.5%	+64.0%
Q4 20	38M	+23.9%	+72.5%
Q2 21	37M	-4.7%	+64.8%
Q4 21	40M	+8.4%	+47.9%
Q2 22	41M	+3.2%	+32.2%
Q4 22	42M	+2.9%	+9.7%
Q2 23	42M	+0.0%	+15.1%
Q4 23	49M	+15.7%	+22.9%
Q2 24	52M	+6.8%	+27.2%
Q4 24	52M	0.0%	+23.7%
Q2 25	109M	+109.4%	+158.9%
Q4 25	637M	+485.4%	+1209.4%

Shares Outstanding

Revenue Per Employee

Period	Revenue/Employee	Employees
Q2 18	—	—
Q4 18	—	—
Q2 19	—	—
Q4 19	—	—
Q2 20	—	—
Q4 20	$2.6K	94
Q2 21	$808	94
Q4 21	$45.2K	105
Q2 22	$746	105
Q4 22	$159.6K	113
Q2 23	$68.5K	113
Q4 23	$157.2K	123
Q2 24	$26.0K	123
Q4 24	$64.0K	118
Q2 25	$44.1K	118
Q4 25	-$2.2K	77

Revenue / Employee